2013
The therapeutic potential of immune cross‐talk in leishmaniasis
Hartley M, Kohl K, Ronet C, Fasel N. The therapeutic potential of immune cross‐talk in leishmaniasis. Clinical Microbiology And Infection 2013, 19: 119-130. PMID: 23398405, DOI: 10.1111/1469-0691.12095.Peer-Reviewed Original ResearchConceptsMetastatic leishmaniasisCutaneous leishmaniasisLeishmania parasitesSelf-healing lesionsProtozoan parasitic diseaseEffective antileishmanial drugsSpecies of LeishmaniaDestructive lesionsImmune homeostasisCurrent treatmentTherapeutic strategiesImmune pathwaysNew drug targetsTherapeutic potentialParasitic diseasesAntileishmanial drugsLeishmaniasisLesionsPrevalent formDiseaseDrug targetsRNA virusesTreatmentVariable effectsParasitesDetection of Leishmania RNA Virus in Leishmania Parasites
Zangger H, Ronet C, Desponds C, Kuhlmann FM, Robinson J, Hartley MA, Prevel F, Castiglioni P, Pratlong F, Bastien P, Müller N, Parmentier L, Saravia NG, Beverley SM, Fasel N. Detection of Leishmania RNA Virus in Leishmania Parasites. PLOS Neglected Tropical Diseases 2013, 7: e2006. PMID: 23326619, PMCID: PMC3542153, DOI: 10.1371/journal.pntd.0002006.Peer-Reviewed Original ResearchConceptsLeishmania RNA virusCutaneous leishmaniasisSkin lesionsPresence of LRVHyper-inflammatory immune responsePrimary skin lesionsUlcerated skin lesionsOverall exacerbationsSignificant morbidityInfected miceLesion biopsyRNA virusesSecondary lesionsImmune responseHigh riskNew World Leishmania speciesAggressive phenotypeLeishmania strainsLeishmania parasitesPatient samplesViral detectionMonoclonal antibodiesNasopharyngeal tissuesParasite strainsMetastatic phenotype
2012
Leishmania RNA virus: when the host pays the toll
Hartley M, Ronet C, Zangger H, Beverley S, Fasel N. Leishmania RNA virus: when the host pays the toll. Frontiers In Cellular And Infection Microbiology 2012, 2: 99. PMID: 22919688, PMCID: PMC3417650, DOI: 10.3389/fcimb.2012.00099.Peer-Reviewed Original ResearchConceptsToll-like receptor 3Mucocutaneous leishmaniasisHyper-inflammatory immune responseLeishmania parasitesPotent innate immunogenExperimental animal modelsType 1 interferonLeishmania RNA virusAnti-leishmanial drugsMetastatic leishmaniasisDestructive inflammationMetastatic complicationsMetastatic diseaseInflammatory cascadeInflammatory stateRNA virusesSecondary lesionsImmune responseAnimal modelsClinical isolatesDisease severityReceptor 3Leishmania guyanensisMetastatic factorsClinical interventions